Latest news with #Pathology
Business Wire
27-06-2025
- Health
- Business Wire
CAP: Improving Health Around the World, One Lab at a Time
NORTHFIELD, Ill.--(BUSINESS WIRE)--Reliable diagnostic testing is essential to good medical care, but many laboratories worldwide still face barriers to delivering consistent, high-quality results. To close that gap the College of American Pathologists (CAP) is working with hospitals to improve lab performance, bringing critical support where it's needed most. Through its Laboratory Accreditation Program, the CAP partners with labs in developing countries to increase quality and safety. The program helps laboratories meet internationally recognized standards, ensuring that test results are accurate, consistent, and useful for making the right medical decisions. 'Laboratory accreditation is one of the most effective ways to improve care,' said Gail H. Vance, MD, FCAP, chair of the CAP Foundation Global Pathology Committee (GPC). 'It gives labs a proven path to quality, and it helps more patients get the right diagnosis, no matter where they live.' As part of the Global Pathology article series, curated by the GPC, a new article in the July issue of the Archives of Pathology & Laboratory Medicine highlights one such effort: Vinmec Times City International Hospital in Hanoi, Vietnam. In 2022, Vinmec became the first hospital in the country to earn both CAP accreditation and Joint Commission International certification. Today, its anatomic pathology laboratory performs more than: 25,000 gynecologic cytology samples 10,000 small biopsy specimens 3,000 nongynecologic cytology samples 1,500 surgical specimens 500 immunohistochemistry samples 300 frozen sections The CAP worked closely with Vinmec's pathologists and lab team over several years, helping them make lasting improvements in areas like staff training, test validation, and day-to-day lab management. These changes not only strengthened care at one hospital, but they set a new standard for labs across the region. A separate article in Archives highlights the CAP Foundation's role in supporting this broader effort. Through training, grants, and educational access, the CAP Foundation equips pathologists in under-resourced regions with tools to strengthen diagnostics and support better outcomes via their grant and awards programs and webinars. These programs complement CAP's accreditation work by helping frontline pathologists implement and sustain quality improvements in their own communities. From Southeast Asia to Sub-Saharan Africa and beyond, the CAP's partnerships are helping laboratories deliver more accurate diagnoses and better care for patients everywhere. As the CAP and the CAP Foundation continue to expand their global reach, their programs are closing diagnostic gaps and helping build healthier communities. Talk to an expert: Dr. Gail Vance is available to discuss the role of lab accreditation in improving care worldwide. For interviews, contact media@ About the College of American Pathologists As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, and to watch pathologists at work and see the stories of the patients who trust them with their care. About the College of American Pathologists Foundation The CAP Foundation is the philanthropic arm of the College of American Pathologists, dedicated to improving people's health by developing tomorrow's pathology leaders and mobilizing pathologists to expand health equity in medically underserved communities within the US and globally. The Foundation's Global Pathology Committee advances this mission internally by supporting pathologists in low-resource settings through grants, mentorship, and collaborative initiatives. For more information, visit
Time of India
14-05-2025
- Business
- Time of India
Metropolis Q4 net profit drops 19%, reports no margin gain from Core Diagnostics
Mumbai: Pathology laboratory chain Metropolis Healthcare reported a 19 per cent year-on-year (YoY) decline in net profit to ₹29 crore in the quarter ended March 2025. While the company revenue from operations went up 10 per cent YoY to ₹345 crore, both Profit (8.5 per cent) and adjusted EBITDA margins (24.3 per cent) reflected a dip against the corresponding period. As per the company investors presentation 'the reported EBITDA and PAT (Profit After Tax) were impacted due to one off expenses related to 3 acquisitions, Costs linked to legal and professional fees for tax cases and other small provisions for Inventory.' The company's profit and loss statement that from its total quarterly revenue it incurred a one-time expense of ₹21 crore. During the quarter the company reported 'NIL margin from one if its recent acquisition Core Diagnostics and lower than usual revenue in February in its focus markets.' In December the Pathology chain had acquired 100 per cent stakes of the Delhi-based Core Diagnostics for ₹246 crore. However, the company has maintained a positive outlook for its recent acquisitions. 'We are confident that our recent acquisitions will generate strong returns and fuel the next phase of growth. in specialty testing, expand our B2C footprint, and strengthen our regional presence in North India.' Ameera Shah , Executive Chairperson and Whole-time Director, Metropolis Healthcare Limited, commented. For the full fiscal year the company revenue from operations went up 10 per cent YoY to ₹1,331 crore, while the net profit reported an increase of 14 per cent to ₹146 crore, against the previous fiscal. The current revenue ratio between the company's B2B and B2C services stands at 45:55 and in the last fiscal the two segments reported a YoY increase of 12 per cent and 17 per cent respectively. At the end of FY25 the company portfolio represents 210 clinical labs and is further looking to expand its network. 'With a differentiated portfolio in high-growth segments, and a deeper penetration across key regions, Metropolis is well positioned to capitalize on emerging opportunities and drive long-term stakeholder value,' said Shah. 'As we look ahead, our focus is on strengthening our presence in key cities, expanding digital access, and advancing evidence-based preventive care,' Surendran Chemmenkotil, CEO, Metropolis Healthcare, added.
